By Karlee Weinmann ( October 28, 2014, 11:29 AM EDT) -- Pfizer Inc. said Tuesday that strong performance from its cancer drugs and in emerging markets have pushed its third-quarter earnings above expectations, but did not hint at any major M&A plays in the wake of its failed $118 billion push to merge with AstraZeneca PLC....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.